Evidence map›Paper›PMID 30814254›Full record

ArticleThe Journal of biological chemistry2019

Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.

Jason C McCoy, Ryan G Walker, Nathan H Murray, Thomas B Thompson

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Refining theAnimals : an open access journal from MDPI · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Structural biology of the TGFβ family.Experimental biology and medicine (Maywood, N.J.) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jason C McCoyFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267.
Ryan G WalkerFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267.
Nathan H MurrayFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267.
Thomas B ThompsonFrom the Department of Molecular Genetics, Biochemistry, and Microbiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267 Tom.Thompson@uc.edu.ORCID 0000-0002-7041-5047
University of Cincinnati · USHarvard University Press · USUniversity of Wisconsin–Madison · US

Funding

Structure-Function Investigation of DAN-mediated BMP AntagonismR01GM114640 · NIGMS · UNIVERSITY OF CINCINNATI · PI THOMPSON, THOMAS B · 2015 to 2018
$1.7M
Structural insight into the signaling and regulation of GDF8 and GDF11R01GM127726 · NIGMS · UNIVERSITY OF CINCINNATI · PI THOMPSON, THOMAS B · 2018 to 2019
$744k
NIGMS NIH HHS R01 GM114640NIGMS NIH HHS R01 GM127726
6 · The paper itself

Abstract

Growth differentiation factor 8 (GDF8; also known as myostatin) and GDF11 are closely related members of the transforming growth factor β (TGF-β) family. GDF8 strongly and negatively regulates skeletal muscle growth, and GDF11 has been implicated in various age-related pathologies such as cardiac hypertrophy. GDF8 and GDF11 signaling activities are controlled by the extracellular protein antagonists follistatin; follistatin-like 3 (FSTL3); and WAP, follistatin/kazal, immunoglobulin, Kunitz, and netrin domain-containing (WFIKKN). All of these proteins contain a follistatin domain (FSD) important for ligand binding and antagonism. Here, we investigated the structure and function of the FSD from murine WFIKKN2 and compared it with the FSDs of follistatin and FSTL3. Using native gel shift and surface plasmon resonance analyses, we determined that the WFIKKN2 FSD can interact with both GDF8 and GDF11 and block their interactions with the type II receptor activin A receptor type 2B (ActRIIB). Further, we solved the crystal structure of the WFIKKN2 FSD to 1.39 Å resolution and identified surface-exposed residues that, when substituted with alanine, reduce antagonism of GDF8 in full-length WFIKKN2. Comparison of the WFIKKN2 FSD with those of follistatin and FSTL3 revealed differences in both the FSD structure and position of residues within the domain that are important for ligand antagonism. Taken together, our results indicate that both WFIKKN and follistatin utilize their FSDs to block the type II receptor but do so via different binding interactions.

Indexed as

Activin Receptors, Type IIAnimalsBone Morphogenetic ProteinsCarrier ProteinsCrystallography, X-RayFollistatin-Related ProteinsGrowth Differentiation FactorsHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsMiceMyostatinSurface Plasmon ResonanceActivin Receptors, Type IIactivin receptor type II-BBone Morphogenetic ProteinsCarrier ProteinsFollistatin-Related ProteinsFstl3 protein, mouseGdf11 protein, mouseGprasp1 protein, mouseGrowth Differentiation FactorsIntracellular Signaling Peptides and ProteinsMstn protein, mouseMyostatinantagonismfollistatinGDF11GDF8inhibitormuscle developmentmyostatinprotein structurestructural biologytissue homeostasistransforming growth factor beta (TGF-β)WFIKKNX-ray crystallography

Identifiers

PMID30814254
PMCPMC6484119
OpenAlexW2916418427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.